uBriGene Biosciences Partners with BriSTAR Immunotech on Universal STAR-T Cell Therapy CDMO

uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership with BriSTAR Immunotech, a clinical-stage cell therapy company, to provide full-process CDMO services for universal STAR-T therapy targeting severe autoimmune diseases. The collaboration integrates uBriGene’s AAV vector manufacturing expertise with BriSTAR’s STAR-T cell technology to overcome autologous therapy bottlenecks and accelerate clinical translation of this next-generation cell therapy platform.

Partnership Structure

Technology Integration & Innovation

Target Indications & Market Context

• Autoimmune Cell Therapy Gap: Autologous CAR-T (Kymera, Cabaletta) demonstrates efficacy but 3-4 week manufacturing delays treatment; universal STAR-T offers immediate administration for life-threatening autoimmune crises
• China ATMP Ecosystem: Partnership exemplifies vertical integration—BriSTAR innovation + uBriGene manufacturing—reducing reliance on foreign CDMOs (Lonza, Catalent) and accelerating domestic clinical timelines

Development & Regulatory Strategy

Forward‑Looking Statements
This brief contains forward‑looking statements regarding STAR-T therapy clinical development, universal cell therapy manufacturing scalability, and autoimmune disease market penetration. Actual results may differ due to allogeneic cell therapy immune rejection risks, AAV vector immunogenicity, and competitive dynamics with autologous CAR-T programs.-Fineline Info & Tech